Patents by Inventor Rodney SHACKELFORD

Rodney SHACKELFORD has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Methods and therapeutics to regulate hydrogen sulfide bioavailability
    Patent number: 11510925
    Abstract: The presently claimed invention is related to compositions and methods for treating H2S related diseases comprising administering a pharmacologically effective amount of pharmaceutical composition containing a first therapeutic, wherein the first therapeutic includes one of an ATR kinase inhibitor and an ATR kinase promotor. According to further embodiments the H2S related disease is one of cancer, cardiovascular disease, acute inflammation, chronic inflammation, and neurological disease.
    Type: Grant
    Filed: November 13, 2019
    Date of Patent: November 29, 2022
    Assignee: Board of Supervisors of Louisiana State University
    Inventors: Christopher G. Kevil, Rodney Shackelford
  • METHODS AND THERAPEUTICS TO REGULATE HYDROGEN SULFIDE BIOAVAILABILITY
    Publication number: 20200171041
    Abstract: The presently claimed invention is related to compositions and methods for treating H2S related diseases comprising administering a pharmacologically effective amount of pharmaceutical composition containing a first therapeutic, wherein the first therapeutic includes one of an ATR kinase inhibitor and an ATR kinase promotor. According to further embodiments the H2S related disease is one of cancer, cardiovascular disease, acute inflammation, chronic inflammation, and neurological disease.
    Type: Application
    Filed: November 13, 2019
    Publication date: June 4, 2020
    Inventors: Christopher G. KEVIL, Rodney SHACKELFORD
  • Methods and compositions for treatment of ataxia-telangeictasia
    Publication number: 20050009760
    Abstract: This invention relates to the methods and pharmaceutical compositions for treating diseases or disorders associated with oxidative stress and/or genomic instability. In particular, the invention relates to methods for treating ataxia-telangeictasia (AT) and such disease states by administering a therapeutically effective amount of a chelating agent to increase genomic stability and/or decrease oxidative stress.
    Type: Application
    Filed: July 11, 2003
    Publication date: January 13, 2005
    Inventors: Suming Wang, Rodney Shackelford